Technical Articles

The development history of KRAS inhibitors spans over thirty years, with the first two decades nearly stagnant and the last decade witnessing an explosion. The turning point lies in the new understanding of KRAS's dynamic conformations and advancements in chemical technologies—particularly the application of covalent chemistry, fragment-based drug design, and targeted protein degradation.